Janus Kinase Inhibition in the Aicardi-Goutières Syndrome

N Engl J Med. 2020 Sep 3;383(10):986-989. doi: 10.1056/NEJMc2001362.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Age of Onset
  • Autoimmune Diseases of the Nervous System / drug therapy*
  • Azetidines / adverse effects
  • Azetidines / therapeutic use*
  • Biomarkers
  • Child
  • Child Development / drug effects
  • Child, Preschool
  • Dose-Response Relationship, Drug
  • Female
  • Gene Expression / drug effects
  • Humans
  • Infant
  • Interferons / genetics
  • Interferons / metabolism
  • Janus Kinase Inhibitors / adverse effects
  • Janus Kinase Inhibitors / therapeutic use*
  • Least-Squares Analysis
  • Male
  • Nervous System Malformations / drug therapy*
  • Purines
  • Pyrazoles
  • Sulfonamides / adverse effects
  • Sulfonamides / therapeutic use*
  • Young Adult

Substances

  • Azetidines
  • Biomarkers
  • Janus Kinase Inhibitors
  • Purines
  • Pyrazoles
  • Sulfonamides
  • Interferons
  • baricitinib

Supplementary concepts

  • Aicardi-Goutieres syndrome